No Data
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present
Express News | Intellia Therapeutics Announced The Acceptance Of An Oral Presentation From The Phase 1 Portion Of The Ongoing NTLA-2002 Phase 1/2 Study At The European Academy Of Allergy And Clinical Immunology Congress 2024
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale
Express News | Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 30.98% Wedbush → $29 Reiterates Neutral → Neutral 02/23/2024 44.53% Goldman Sachs → $32 Downgra